Unfavorable Intermediate‐Risk Prostate Cancer and the Odds of Upgrading to Gleason 8 or Higher at Prostatectomy
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Genitourinary Cancer"
DOI: 10.1016/j.clgc.2016.06.001
Abstract: Micro‐Abstract In order to decide whether to administer radiation and a short or long course of androgen deprivation therapy in men with unfavorable intermediate‐risk prostate cancer, multiparametric magnetic resonance imaging could be considered when the… read more here.
Keywords: gleason; score higher; intermediate risk; unfavorable intermediate ... See more keywords
A randomized, non-comparative, phase II multicentric trial on short-term darolutamide (ODM-201) concomitant to radiation therapy for patients with unfavorable intermediate-risk prostate cancer: DARIUS (AFU-GETUG P15).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.4_suppl.tps349
Abstract: TPS349 Background: Androgen Deprivation Therapy (ADT) with external beam radiation therapy (EBRT) is a standard of care for patients (pts) with unfavorable intermediate-risk prostate cancer (Pca). However, ADT generates side effects with 30% decrease of… read more here.
Keywords: intermediate risk; unfavorable intermediate; pca; radiation therapy ... See more keywords